Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

Fig. 4

IPWRA Analysis for CTSQ Scores and Physician Satisfaction with Treatment. Mean scores for 3 CTSQ domains (A) and proportion of physicians satisfied with treatment (B) adjusted for patient demographic and clinical variables by IPWRA for patients treated with PARPi or chemotherapy. CTSQ, Cancer Therapy Satisfaction Questionnaire; IPWRA, inverse-probability–weighted regression adjustment; PARPi, poly (ADP-ribose) polymerase inhibitors. *Includes platinum- and non–platinum-based regimens. Error bars represent standard error

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us